2012 Current Cancer Dedicated to bringing the latest news and information on cancer diagnosis, treatment and prevention.

The sole resource to focus on cutting-edge biomolecular approaches to cancer therapy. Presenting the latest research in cancer biology, Cancer Epigenetics reveals the most promising developments in novel therapeutics and diagnostic options for cancer patients. Featuring contributions from international authorities in diverse disciplines, the book offers clear therapeutic approaches and applications and facilitates collaboration between ...

ATLANTA – Scientists at Georgia State University have found that whole ginger extract has promising cancer-preventing activity in prostate cancer. The first of its kind study looks at the anti-cancer properties of ginger as a whole, rather than that of individual compounds found in the plant. The lab of Ritu Aneja, associate professor of biology, ...

DARA BioSciences, Inc. DARA announced today that its investigational drug KRN5500 has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of chemotherapy-induced neuropathic pain in patients with cancer. The FDA’s Fast Track program is designed to facilitate the development and expedite the review of new drugs that ...

Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of ADCETRISTM (brentuximab vedotin) for two indications: (1) the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients ...

World Circulating Tumor Cells Summit Technologies and techniques to practically apply CTCs in the clinic and unleash their full commercial potential 8th – 10th November San Diego The application of CTCs as a predictive biomarker and non-invasive cancer diagnostic holds great promise for drug developers; and the technologies enabling you to achieve this are advancing ...